BASIC RESEARCH
Preliminary report: one of the PD-1 gene variants may be a valuable marker for colorectal cancer
Submission date: 2017-12-13
Final revision date: 2018-03-23
Acceptance date: 2018-03-24
Publication date: 2018-04-30
Arch Med Sci Civil Dis 2018;3(1):34-40
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Introduction: Programmed death-1 (PD-1), an important immunosuppressive molecule, plays a key role in tumor-cell-mediated immune escape. The present study aimed to investigate the role of PD-1.5 (C/T) gene polymorphisms on the susceptibility and progression of colorectal cancer (CRC).
Material and methods:
In this study, the PD-1.5 C/T polymorphism was investigated in 99 CRC patients and 150 healthy individuals as controls by nested polymerase chain reaction-restriction fragment length polymorphism method
Results:
The distributions of PD-1.5 (C/T) genotypes and alleles were in agreement with Hardy–Weinberg equilibrium in controls (p>0.05) but not in CRC patients (p=0.02). We found a statistical significance difference between CRC patients and controls for the genotypic distribution of PD-1.5(C/T) genotypes (p=0.003) and also for alleles (p=0.004). The patients who have T allele have increased according to the controls (p=0.001). The patients who have C allele with distance metastasis have increased heterozygous CT genotype of PD-1.5 (C/T) polymorphism than those with no metastasis (p<0.001). We also detected the increased CC genotype in patients who have angiolymphatic invasion (p=0.043). The patients who have mucineous component have increased frequency of T allele than those with the absence of mucineous component (p=0.023).
Conclusions:
Our results have shown significant associations between PD-1.5 genotypes and CRC susceptibility and progression of the disease.
Introduction: Programmed death-1 (PD-1), an important immunosuppressive molecule, plays a key role in tumor-cell-mediated immune escape. The present study aimed to investigate the role of PD-1.5 (C/T) gene polymorphisms on the susceptibility and progression of colorectal cancer (CRC).
Material and methods:
In this study, the PD-1.5 C/T polymorphism was investigated in 99 CRC patients and 150 healthy individuals as controls by nested polymerase chain reaction-restriction fragment length polymorphism method
Results:
The distributions of PD-1.5 (C/T) genotypes and alleles were in agreement with Hardy–Weinberg equilibrium in controls (p>0.05) but not in CRC patients (p=0.02). We found a statistical significance difference between CRC patients and controls for the genotypic distribution of PD-1.5(C/T) genotypes (p=0.003) and also for alleles (p=0.004). The patients who have T allele have increased according to the controls (p=0.001). The patients who have C allele with distance metastasis have increased heterozygous CT genotype of PD-1.5 (C/T) polymorphism than those with no metastasis (p<0.001). We also detected the increased CC genotype in patients who have angiolymphatic invasion (p=0.043). The patients who have mucineous component have increased frequency of T allele than those with the absence of mucineous component (p=0.023).
Conclusions:
Our results have shown significant associations between PD-1.5 genotypes and CRC susceptibility and progression of the disease.
REFERENCES (42)
1.
Jorgensen ML, Young JM, Solomon MJ. Optimal delivery of colorectal cancer follow-up care: improving patient outcomes. Patient Relat Outcome Meas 2015; 6: 127-38.
2.
Yin D, Morris CR, Bates JH, German RR. Effect of misclassified underlying cause of death on survival estimates of colon and rectal cancer. J Natl Cancer Inst 2011; 103: 1130-3.
3.
Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int 2015; 2015: 149014.
4.
Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) 2015; 3: 289-97.
5.
Kocian P, Šedivcová M, Drgáč J, et al. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. Hum Immunol 2011; 72: 1022-8.
6.
Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003; 3: 589-96.
7.
Mik M, Dziki L, Malinowska K, Trzcinski R, Majsterek I, Dziki A. Polymorphism of MSH2 Gly322Asp and MLH1 -93G>A in non-familial colon cancer – a case-controlled study. Arch Med Sci 2017; 13: 1295-302.
8.
Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
9.
Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20: 504-11.
10.
Nishimura H, Nose M, HiaiH, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-51.
11.
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-24.
12.
Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381-5.
13.
Erfani N, Razmkhah M, Talei AR, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 2006; 165: 114-20.
14.
Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947-53.
15.
Finger LR, Pu J, Wasserman R, et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 1997; 197: 177-87.
16.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
17.
Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-8.
18.
Savabkar S, Azimzadeh P, Chaleshi V, et al. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. Gastroenterol Hepatol Bed Bench 2013; 6: 178-82.
19.
Tang W, Chen Y, Chen S, et al. Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma. Int J Clin Exp Med 2015; 8: 8086-93.
20.
Mojtahedi Z, Mohmedi M, Rahimifar S, Erfani N, Hosseini SV, Ghaderi A. Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. Gene 2012; 508: 229-32.
21.
Hua Z, Li D, Xiang G, et al. PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat 2011; 129: 195-201.
22.
Haghshenas MR, Naeimi S, Talei A, et al. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep 2011; 38: 4205-10.
23.
Qiu, H, Zheng L, Tang W, Yin P, Cheng F, Wang L. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clin Biochem 2014; 47: 612-7.
24.
Li Z, Li N, Zhu Q, et al. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infect Genet Evol 2013; 14: 240-6.
25.
Li XF, Jiang XQ, Zhang JW, Jia YJ. Association of the programmed cell death-1 PD1.5 C>T polymorphism with cervical cancer risk in a Chinese population. Genet Mol Res 2016; 15. DOI: 10.4238/gmr.15016357.
26.
Zlobec I, Karamitopoulou E, Terracciano L, et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One 2010; 5: e14282.
27.
Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 2008; 270: 337-41.
28.
Kong EK, Prokunina-Olsson L, Wong WH, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005; 52: 1058-62.
29.
Flores S, Beems M, Oyarzun A, Carrasco E, Perez F. Programmed cell death 1 (PDCD1) gene polymorphisms and type 1 diabetes in Chilean children. Rev Med Chil 2010; 138: 543-50.
30.
Lee SH, Lee YA, Woo DH, et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 2006; 8: R163.
31.
Cooper JD, Smyth DJ, Bailey R, et al. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med Genet 2007; 8: 71.
32.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
33.
Li Y, Zhang HJ, Kang S, Zhou RM, Wang N. The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients’ outcomes. Gynecol Oncol 2017; 144: 140-5.
34.
Yin L, Guo H, Zhao L, et al. The programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with non-small cell lung cancer risk in a Chinese Han population. Int J Clin Exp Med 2014; 7: 5832-6.
35.
Namavar Jahromi F, Samadi M, Mojtahedi Z, Haghshenas MR, Taghipour M, Erfani N. Association of PD-1.5 C/T, but not PD-1.3 G/A, with malignant and benign brain tumors in Iranian patients. Immunol Invest 2017; 46: 469-80.
36.
Zuniga J, Torres-García D, Jimenez L, et al. PDCD1 gene polymorphisms in different Mexican ethnic groups and their role in the susceptibility to hypersensitivity pneumonitis. Clin Biochem 2010; 43: 929-31.
37.
Haghshenas MR, Dabbaghmanesh MH, Miri A, Ghaderi A, Erfani N. Association of PDCD1 gene markers with susceptibility to thyroid cancer. J Endocrinol Invest 2017; 40: 481-6.
38.
Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J. Programmed cell death-1 polymorphisms decrease the cancer risk: a meta-analysis involving twelve case-control studies. PLoS One 2016; 11: e0152448.
39.
Tang W, Wang Y, Jiang H, et al. Programmed death-1 (PD-1) rs2227981C>T polymorphism is associated with cancer susceptibility: a meta-analysis. Int J Clin Exp Med 2015; 8: 22278-85.
40.
Mamat U, Arkinjan M. Association of programmed death-1 gene polymorphism rs2227981 with tumor: evidence from a meta analysis. Int J Clin Exp Med 2015; 8: 13282-8.
41.
Lin SC, Yen JH, Tsai JJ, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004; 50: 770-5.
42.
Mohammed ZM, McMillan DC, Edwards J, et al. The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol 2013; 13: 31.
Share
RELATED ARTICLE
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
